Physician profile
Bernard N Robinowitz
NPI 1598760712
$13,860.76
in general payments reported to CMS, 2019-2025
29 companies · $3,434 in 2025
The $3,434 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $386 · 2021: $99.57 · 2022: $1,585 · 2023: $3,003 · 2024: $3,564 · 2025: $3,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,731 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,730.52 |
| Education | $270.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,773.86 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,615.28 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,305.21 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,250.32 | 2019-2025 | |
| Lilly USA, LLC | $1,182.58 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $1,089.15 | 2019-2025 | |
| Ucb, INC. | $828.05 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $814.36 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $581.79 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $432.20 | 2019-2025 | Blu-U, Odomzo |
| Leo Pharma INC. | $373.47 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $362.37 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $258.65 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $203.48 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $191.29 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.82 | 2023-2025 | Siliq, Jublia, Cabtreo |
| Organon LLC | $91.46 | 2025 | Vtama |
| Kyowa Kirin, INC. | $58.42 | 2022-2024 | Poteligeo |
| Biocon Biologics INC | $51.30 | 2025 | Yesintek |
| Celgene Corporation | $38.53 | 2019 | |
| Organogenesis INC. | $34.72 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $33.87 | 2019 | |
| Krystal Biotech INC | $25.42 | 2024 | Vyjuvek |
| Janssen Scientific Affairs, LLC | $24.02 | 2019 | |
| Incyte Corporation | $18.04 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2023 | Cyltezo |
| Dermira, INC. | $14.85 | 2019 | |
| Mayne Pharma Commercial LLC | $14.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Robinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.